Welcome to our dedicated page for HNSA news (Ticker: HNSA), a resource for investors and traders seeking the latest updates and insights on HNSA stock.
Hansa Biopharma AB (HNSA) news covers developments at a commercial-stage biopharmaceutical company focused on rare immunological conditions. Based in Lund, Sweden, with operations in Europe and the U.S., Hansa Biopharma reports on progress across its proprietary IgG-cleaving enzyme technology platform, including transplantation, autoimmune diseases and gene therapy applications.
News for HNSA frequently highlights clinical and regulatory milestones for imlifidase, a first-in-class IgG antibody-cleaving enzyme therapy that has been shown to enable kidney transplantation in highly sensitized patients. Updates include data from the pivotal U.S. Phase 3 ConfIdeS trial in kidney transplantation, long-term follow-up analyses of imlifidase-enabled transplants, and the company’s submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for desensitization of highly sensitized adult patients undergoing deceased donor kidney transplantation.
Investors following HNSA news can also expect information on IDEFIRIX product performance in approved markets, progress of next-generation asset HNSA-5487, and updates from gene therapy-related studies where imlifidase is used to reduce anti-AAV antibodies. Company announcements regularly cover participation in scientific congresses, virtual scientific and investor events, and corporate developments such as executive appointments and financing transactions.
This news feed provides a centralized view of Hansa Biopharma’s disclosures on its clinical programs, regulatory interactions, commercial activities and strategic initiatives linked to its IgG-cleaving enzyme platform. Readers interested in HNSA stock and the company’s role in rare immunological conditions can use this page to monitor key trial readouts, regulatory milestones and other material company updates over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will release its interim report for January-March 2023 on April 20, 2023, at 8:00 CET. Following the report, a telephone conference hosted by CEO Søren Tulstrup and CFO Donato Spota will take place at 14:00 CET (8:00 AM EST) to discuss the results and provide a business update. Interested participants can access the call using the provided dial-in numbers from Sweden, the UK, and the US. The presentation slides will be available on the company's website during the call and online afterward. Key upcoming financial events include the Redeye Investor Forum and the Half-year report on July 20, 2023. For more information, contact Klaus Sindahl or Stephanie Kenney.
Hansa Biopharma has completed enrollment for its phase 2 study of imlifidase in patients with Guillain-Barré Syndrome (GBS). This study, conducted across the UK, France, and the Netherlands, assesses the safety and efficacy of imlifidase alongside standard treatment. Top-line data is anticipated in the second half of 2023, with a comparative analysis with the International Guillain-Barré Syndrome Outcome Study cohort planned for 2024. GBS affects 1-2 in 100,000 people yearly and can lead to severe disability. Imlifidase previously received Orphan Drug Designation from the FDA for GBS treatment in 2018.
Hansa Biopharma (HNSA) announced on March 29, 2023, that the Spanish Minister of Health granted reimbursement for Idefirix®, an innovative treatment for desensitizing highly sensitized adult patients before kidney transplants. This decision follows its conditional approval by EMA in August 2020. With approximately 20% of nearly 4,000 kidney transplant waitlist patients in Spain being highly sensitized, this approval allows for greater access to potentially lifesaving transplants. Now available in five key Western European countries, Idefirix® addresses a significant unmet medical need for these patients.
Hansa Biopharma has appointed Matthew Shaulis as the new Chief Commercial Officer and President of U.S. operations, effective March 16, 2023. Shaulis brings over 20 years of experience in the pharmaceutical sector, having held key positions at Pfizer and other major companies. His role is critical as Hansa aims to enhance its commercial capabilities and focus on launching imlifidase in the U.S. market. CEO Søren Tulstrup highlighted this appointment as a strategic move to ensure a high-performing commercial function, reflecting Hansa's commitment to growth in the biotechnology sector.